Blog

Mark Lewis: Myriam Chalabi reporting the NICHE-2 trial in NEJM

Photo of Myriam Chalabi from eurekalert.org

Jun 7, 2024, 14:08

Mark Lewis: Myriam Chalabi reporting the NICHE-2 trial in NEJM

Mark Lewis shared on X: .

“TLC: don’t go chasing waterfalls

Myriam Chalabi reporting the NICHE-2 trial with 95% of locally advanced, mismatch repair-deficient colon cancer responding (pathologically!) to neoadjuvant immunotherapy in NEJM.”

Source: Mark Lewis/X

Mark A. Lewis is the Director of Gastrointestinal Oncology at Intermountain Healthcare in Utah, the Co-Chair of adolescent and young adult (AYA) oncology in the SWOG cooperative group, and the Vice President of American Multiple Endocrine Neoplasia Support. Dr. Lewis is also a well-known patient advocate and social media influencer.

cancer Colon cancer Gastrointestinal Oncology at Intermountain Healthcare in Utah mismatch repair-deficient colon cancer Myriam Chalabi NEJM neoadjuvant immunotherapy NICHE-2 trial OncoDaily Oncology

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage